Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) FCF Margin (2017 - 2025)

Arcus Biosciences has reported FCF Margin over the past 9 years, most recently at 366.67% for Q4 2025.

  • For Q4 2025, FCF Margin rose 2179.0% year-over-year to 366.67%; the TTM value through Dec 2025 reached 195.95%, down 12773.0%, while the annual FY2025 figure was 195.95%, 12773.0% down from the prior year.
  • FCF Margin for Q4 2025 was 366.67% at Arcus Biosciences, up from 373.08% in the prior quarter.
  • Over five years, FCF Margin peaked at 3616.67% in Q1 2022 and troughed at 812.2% in Q2 2021.
  • A 5-year average of 121.68% and a median of 254.66% in 2022 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: soared 435609bps in 2022 and later tumbled -402467bps in 2023.
  • Year by year, FCF Margin stood at 16.45% in 2021, then crashed by -1098bps to 197.06% in 2022, then tumbled by -161bps to 514.29% in 2023, then grew by 24bps to 388.46% in 2024, then increased by 6bps to 366.67% in 2025.
  • Business Quant data shows FCF Margin for RCUS at 366.67% in Q4 2025, 373.08% in Q3 2025, and 83.75% in Q2 2025.